Two pharmaceutical companies are about to go public, behind the shareholders of Tian group have a high capital figure

"Pharmaceutical Network Industry Dynamics" Recently, the upcoming listing of Jia and Bio and Yunding Xinyao has received the attention of the industry.
from the shareholder structure, the shareholders behind both companies have a strong pharmaceutical professional background, and can see the well-known investment institutions gaoxuan capital figure.
and BioGa and Bio, is a biopharmaceutical company focused on the development and commercialization of oncology and autoimmune drugs.
as of September 13, 2020, Jiahe Bio has established a product pipeline of 15 targeted drug candidates with great commercial potential in China and covers known and new biological path paths.
addition, Jia and Bio are currently conducting 17 clinical trials in Asia and are expected to submit two NDAs to the National Drug Administration and four INDs to the National Drug Administration and the U.S. Food and Drug Administration in the next 12 to 18 months.
in terms of research and development progress, Jia and Bio in the second half of 2020 alone have three products expected to be commercialized, a good point of view.
currently, there are six major drug candidates, including GB491 (lerociclib), GB221, geptanolimab (GB226), GB492, GB242 and GB223.
covers a wide range of tumors, autoimmune and other chronic disease adaptation areas.
three of these drugs have entered phase III clinical trials and are expected to be gradually approved for commercialization in 2021.
the industry believes that these candidates are highly promising drugs with targeted paths.
from the future sales prospects, Jiahe biological products pipeline products are excellent, gold content is very high.
, HHJH and HM Healthcare, which own 36.07 per cent of Jia and Bio, are the largest shareholders, according to the company's prospectine prospectine.
, the second largest share is Kangjia Medical and Kang and Medical, a subsidiary of East Connbey, which together own 16.07 per cent of Jia and Bio.
, the third-largest shareholder in the company, controls 14.34 per cent of Jia and Bio through its wholly owned subsidiary, Voga.
, a clinical late-stage biopharmaceutical company, was founded in July 2017.
has established subsidiaries in China to promote research and development, entered into strategic agreements with a number of well-known pharmaceutical companies to introduce international drugs and has been approved and commercialized in China, and currently has a portfolio of cancer, immunology, cardionephal diseases and infectious diseases.
prospectine shows that the company currently has six drug candidates in China to carry out or enter the registration trial, covering tumors, immunology, cardionephrophro disease and infectious diseases.
company has a wealth of product pipelines in the clinical late stage, and have the potential to become the first of its kind or the best products of its kind.
Among them, the core product Trodelvy's main battleground will be in the three-negative breast cancer no man's land, the current treatment plan in the three-negative breast cancer in the country mainly chemotherapy but the effect is not good, the industry expects Trodelvy will be expected to become the domestic treatment of three-negative breast cancer new program.
valuation, the company's multiple products peaked in 2026-2028 and are expected to reach HK$20 billion valuation as clinical pipeline products move further into the market, according to Anxin International.
but in the short term there is about 30 per cent room for growth.
from the shareholder structure of Yunding Xinyao, The controlling shareholder of Yunding Xinyao is Kangqiao Capital, a well-known healthcare investment institution in Asia, with a 62.40 per cent stake.
, Khonsa Capital owns 3.15 per cent and Palace Investments, a wholly owned subsidiary of Temasek, owns 1.42 per cent.
notable is the strong team of sponsors for both companies.
, Jia and this time the sponsors are Goldman Sachs, JPMorgan Chase and Jefferies, while Yunding Xinyao's sponsors are Goldman Sachs and Bank of America Securities.